Revive Therapeutics (TSE:RVV) has released an update.
Revive Therapeutics is shifting its resources to focus on the development of Bucillamine for infectious diseases and defense against nerve agent exposure, discontinuing its Long COVID diagnostic product development. The company is collaborating with the Canadian Defence R&D in evaluating Bucillamine’s effectiveness in treating nerve agent exposure and is also exploring its potential in treating various viral infections including Mpox.
For further insights into TSE:RVV stock, check out TipRanks’ Stock Analysis page.
